# To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

> **NCT01808339** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Furoate (FF)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01808339
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808339, "To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01808339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*